NCT01043380

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 245 (actual)
• Sponsor: Kumamoto University · Academic / Other
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound \[IVUS\] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.

Conditions

• Hypercholesterolemia
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]	Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
DRUG	Lipitor (Atorvastatin) monotherapy	The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.

Timeline

• Start date: 2010-01-01
• Primary completion: 2014-03-01
• Completion: 2014-09-01
• First posted: 2010-01-06
• Last updated: 2015-04-01

Locations

1 site across 1 country: Japan